Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Bone metastases from renal cell carcinoma (RCC) are a major cause of morbidity. Post hoc analysis has suggested that bone turnover markers can identify patients at risk of skeletal-related events (SREs) among those receiving zoledronic acid. This study sought to evaluate the effect on bone metastases of everolimus alone compared with everolimus plus zoledronic acid.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Genitourin Cancer

Title: Clinical genitourinary cancer

ISSN (Electronic): 1938-0682

ISSN (Print): 1558-7673

Publication date (Electronic): Feb 2015

Volume: 13

Issue: 1

Affiliations

[1 ] Regional Cancer and Blood Centre, Auckland City Hospital, Auckland, New Zealand. Electronic address: ReubenB@adhb.govt.nz.

[2 ] Cancer Trials New Zealand, Discipline of Oncology, University of Auckland, New Zealand.

[3 ] Cancer Trials New Zealand, Discipline of Oncology, University of Auckland, New Zealand; Department of Preventative and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.

[4 ] Regional Cancer and Blood Centre, Auckland City Hospital, Auckland, New Zealand.

[5 ] Midcentral Regional Cancer Treatment Service, Palmerston North Hospital, Palmerston North, New Zealand.

[6 ] Oncology Service, Christchurch Hospital, Christchurch, New Zealand.

[7 ] Regional Cancer Centre, Waikato Hospital, Hamilton, New Zealand.

[8 ] Wellington Blood and Cancer Centre, Wellington Hospital, Wellington, New Zealand.

[9 ] Tauranga Hospital, Tauranga, New Zealand.

[10 ] Department of Medicine, University of Auckland, Auckland, New Zealand.

Article

Publisher Item ID: S1558-7673(14)00136-0

DOI: 10.1016/j.clgc.2014.07.002

PubMed ID: 25163397

SO-VID: 0e6aa5bd-8595-422a-8b28-2de92b8bf308

History

Keywords: Bisphosphonates,Neoplasm metastasis,Randomized controlled trial,Skeletal-related events,Targeted therapy

Data availability:

Keywords: Bisphosphonates, Neoplasm metastasis, Randomized controlled trial, Skeletal-related events, Targeted therapy

Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

Read this article at

Abstract

Related collections

Herbal Medicines Journal (Herb Med J)

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 457

Cited by 20